Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKesson
Cipla
US Department of Justice
Mallinckrodt
Fish and Richardson
Citi
Express Scripts
Cerilliant

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

« Back to Dashboard

Clinical Trials for Dextrose 5% And Electrolyte No. 48 In Plastic Container

Trial ID Title Status Sponsor Phase Summary
NCT00001986 1-Octanol to Treat Essential Tremor Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 1 This study will evaluate the safety and effectiveness of the food additive 1-octanol for treating essential tremor. This disorder, which is an involuntary shaking, usually of the hands, has no satisfactory treatment. It affects more than one of every 100 people in the general population, with the figure climbing to nearly 4 in every hundred among people over 40 years old. In animal studies, 1-octanol reduced chemically induced tremors in rats. This study will test the effects of the accepted daily intake of 1-octanol (1 milligram per kilogram of body weight) on essential tremor in humans. Patients with essential tremor 21 years old and older who wish to enroll in this study will undergo eligibility screening with a medical history and physical examination that includes tests for thyroid, liver and kidney problems. Participants will be randomly assigned to receive either 1-octanol or a placebo (an inactive substance). Patients in both groups will have an intravenous catheter (a thin, plastic tube) placed in an arm vein for collecting blood samples during the study. Those in the 1-octanol group will be given a 1-octanol capsule; the placebo group will receive a look-alike capsule containing no active ingredient. Neither the patient nor the doctor will know which patients are taking 1-octanol or placebo until the end of the study. Tremors will be measured once before the catheter is placed, every 15 minutes during the first 2 hours after taking the capsule, twice during the third hour (30 minutes apart), and once again after 5 hours. The tremors are measured using procedures called accelerometry and surface electromyography. For these procedures, electrodes are taped to the skin; needles are not used. Blood samples will be collected once before taking the capsule, every 15 minutes for the first hour and a half after taking the capsule and again at 2 hours, 4 hours and 5 hours after taking the capsule. Vital signs (blood pressure, pulse, and respiratory rate) will be measured every 15 minutes during the first 2 hours of taking the capsule, every 30 minutes during the third hour, and again at 4 hours and 5 hours. Participants will stay in the hospital overnight for observation and return after 3 days for a follow-up physical examination, including a blood test.
NCT00004328 Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I Completed University of Texas Phase 2 OBJECTIVES: I. Establish the sodium and potassium intake that will maintain a normovolemic state in a patient with pseudohypoaldosteronism. II. Determine the effect of extracellular fluid volume and serum potassium manipulations on exercise tolerance, cardiac function, and endurance. III. Investigate pharmacologic methods of limiting excretion of sodium in urine and sweat.
NCT00004328 Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I Completed National Center for Research Resources (NCRR) Phase 2 OBJECTIVES: I. Establish the sodium and potassium intake that will maintain a normovolemic state in a patient with pseudohypoaldosteronism. II. Determine the effect of extracellular fluid volume and serum potassium manipulations on exercise tolerance, cardiac function, and endurance. III. Investigate pharmacologic methods of limiting excretion of sodium in urine and sweat.
NCT00039988 Treatment of Multiple Sclerosis With Copaxone and Albuterol Completed Autoimmunity Centers of Excellence N/A The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS). MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
NCT00039988 Treatment of Multiple Sclerosis With Copaxone and Albuterol Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS). MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
NCT00072683 “SALT Trial” Study of Ascending Levels of Tolvaptan in Hyponatremia Completed Otsuka Pharmaceutical Co., Ltd. Phase 3 This study’s purpose is to determine whether tolvaptan can safely and effectively return the body’s balance of sodium and water toward normal, and to characterize and quantify the potential clinical benefits of this treatment.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Dextrose 5% And Electrolyte No. 48 In Plastic Container

Condition Name

Condition Name for Dextrose 5% And Electrolyte No. 48 In Plastic Container
Intervention Trials
Colonoscopy 9
Cystic Fibrosis 6
Hepatic Encephalopathy 6
Postoperative Nausea and Vomiting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dextrose 5% And Electrolyte No. 48 In Plastic Container
Intervention Trials
Heart Failure 15
Fibrosis 14
Vomiting 10
Renal Insufficiency 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dextrose 5% And Electrolyte No. 48 In Plastic Container

Trials by Country

Trials by Country for Dextrose 5% And Electrolyte No. 48 In Plastic Container
Location Trials
United States 251
Canada 23
Italy 20
China 18
Mexico 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dextrose 5% And Electrolyte No. 48 In Plastic Container
Location Trials
Texas 20
Ohio 16
Pennsylvania 13
New York 12
Massachusetts 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dextrose 5% And Electrolyte No. 48 In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Dextrose 5% And Electrolyte No. 48 In Plastic Container
Clinical Trial Phase Trials
Phase 4 65
Phase 3 39
Phase 2/Phase 3 10
[disabled in preview] 59
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dextrose 5% And Electrolyte No. 48 In Plastic Container
Clinical Trial Phase Trials
Completed 99
Recruiting 48
Not yet recruiting 27
[disabled in preview] 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dextrose 5% And Electrolyte No. 48 In Plastic Container

Sponsor Name

Sponsor Name for Dextrose 5% And Electrolyte No. 48 In Plastic Container
Sponsor Trials
B. Braun Melsungen AG 6
Takeda 6
The Hospital for Sick Children 6
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dextrose 5% And Electrolyte No. 48 In Plastic Container
Sponsor Trials
Other 264
Industry 72
NIH 10
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Moodys
Dow
Colorcon
UBS
Federal Trade Commission
Queensland Health
Argus Health
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.